Should Pyridostigmine (Mestinon) Be Held During Myasthenia Gravis Crisis?
No, pyridostigmine should NOT be routinely held during myasthenic crisis and can be continued or even initiated as part of crisis management, though it may be temporarily discontinued or withheld in intubated patients.
Evidence-Based Approach
The most recent high-quality guidelines directly address this question. According to the 2022 ESMO guideline 1, pyridostigmine may be discontinued or withheld specifically in cases of intubation, but otherwise can be used throughout crisis management. The 2021 ASCO guidelines 2 explicitly recommend pyridostigmine continuation even in severe Grade 3-4 myasthenic crisis (MGFA class III-V), stating to "follow G2 recommendations" which include pyridostigmine dosing.
Grading-Specific Management
For Grade 2 (Mild-Moderate Weakness):
- Start or continue pyridostigmine at 30 mg PO three times daily
- Gradually titrate up to maximum 120 mg PO four times daily based on symptoms 2
- Add corticosteroids (prednisone 0.5 mg/kg daily) 2
For Grade 3-4 (Myasthenic Crisis with Respiratory Compromise):
- Continue the G2 pyridostigmine regimen 2
- Add IVIG 2 g/kg IV over 5 days (0.4 g/kg/day) OR plasmapheresis for 3-5 days 2
- Continue steroids with taper beginning 3-4 weeks after initiation 2
- ICU-level monitoring with frequent pulmonary function assessment 2
The Intubation Exception
The 2022 ESMO guideline 1 provides the critical nuance: "In case of intubation, pyridostigmine may be discontinued or withheld." This is the only scenario where holding pyridostigmine is specifically recommended. The rationale is that mechanical ventilation provides respiratory support, potentially reducing the immediate need for cholinesterase inhibition while avoiding cholinergic side effects in a critically ill patient.
Supporting Research Evidence
A 2021 systematic review 3 found that continuous IV pyridostigmine or neostigmine can serve as a substitute for IVIG or plasmapheresis when these are unavailable during crisis, with clinical improvement demonstrated across multiple studies. However, the review noted caution is warranted due to potential cardiac arrhythmias and pneumonia.
A 1997 study 4 comparing three therapeutic regimens (pyridostigmine alone, pyridostigmine plus prednisolone, and plasma exchange) found no significant differences in duration of mechanical ventilation or outcomes. Notably, 17% of patients developed severe cardiac arrhythmia (fatal in 6 patients), emphasizing the need for careful cardiac monitoring during crisis management.
Critical Safety Considerations
Medications to Avoid
The guidelines consistently emphasize reviewing and stopping medications that worsen myasthenia 2:
- Beta-blockers
- IV magnesium
- Fluoroquinolones
- Aminoglycosides
- Macrolide antibiotics
Cardiac Monitoring
Mandatory cardiac surveillance is essential given the 17% risk of severe arrhythmias 4. Obtain:
- Baseline troponin and ECG 2
- Consider transthoracic echocardiogram and/or cardiac MRI to evaluate for concomitant myocarditis 2
- Continuous cardiac monitoring during crisis
Renal Function Considerations
In patients with severe renal impairment or on hemodialysis, even standard pyridostigmine doses can cause cholinergic crisis 5. Dose adjustment is necessary in renal failure, as pyridostigmine is primarily renally excreted.
Common Pitfall to Avoid
The most dangerous misconception is that pyridostigmine must be stopped during myasthenic crisis. This outdated practice can worsen symptoms. The modern evidence-based approach is to continue or initiate pyridostigmine as part of multimodal therapy (with IVIG/plasmapheresis and steroids), only withholding it in the specific circumstance of mechanical intubation 1.
The 2018 ASCO guideline 6 and subsequent 2021 update 2 represent the highest quality evidence, consistently recommending pyridostigmine continuation through crisis with dose titration based on clinical response.